Table 3.
Changes in Key Metrics Resulting from Patient Engagement Pre–phase 2.
| Base Case | Effect of Avoiding a Phase 2 Amendment | Chg | Effect of Improving Phase 2 Patient Experience | Chg | Combined Impact | Chg | |
|---|---|---|---|---|---|---|---|
| Launch date | – | 3 mo earlier | 6 mo earlier | 9 mo earlier | |||
| NPV ($MM) | 493 | 518 | 25 | 531 | 38 | 555 | 62 |
| PTRS, % | 15 | 15 | 0 | 20 | 5 | 20 | 5 |
| ENPV ($MM) | 67 | 71 | 4 | 97 | 30 | 102 | 35 |
| Cost to launch ($MM) | 121.1 | 120.6 | –0.5 | 121.1 | 0.0 | 120.6 | –0.5 |
Abbreviations: Chg, change from base case; ENPV, expected net present value; NPV, net present value; PTRS, probability of technical and regulatory success.